Cell Source CEO, Itamar Shimrat on his firm's transition from...

LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections.

http://ift.tt/1uw24BQ